A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 12, 2007

Primary Completion Date

May 30, 2011

Study Completion Date

May 30, 2011

Conditions
Alzheimer's Disease
Interventions
DRUG

GSK933776

"Part A planned doses cohort 1 to cohort 3 0.001 mg/kg, 0.01 mg/kg and 0.1 mg/kg.~Part B planned doses cohort 4 to cohort 7 0.1 mg/kg, 1mg/kg, 3mg/kg and 10 mg/kg"

DRUG

Placebo to match GSK933776

Part A first 2 cohorts 5 patients per cohort 2 placebo and 3 active third cohort part A 2 placebo 6 active. Part B 8 patients per cohort 2 placebo 6 active.

Trial Locations (7)

1478

GSK Investigational Site, Lørenskog

3084

GSK Investigational Site, Heidelberg Heights

4029

GSK Investigational Site, Herston

6160

GSK Investigational Site, Fremantle

SE-205 02

GSK Investigational Site, Malmo

SE-431 41

GSK Investigational Site, Mölndal

se-141 86

GSK Investigational Site, Stockholm

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY